Compare Crispr Therapeutics AG (CRSP) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Simon Property Group Inc — how do they compare? Crispr Therapeutics AG trades at $50.3 (market cap $4.97B), while Simon Property Group Inc trades at $221.67 (market cap $71.76B). The key difference: Simon Property Group Inc is far larger — about 14.4× Crispr Therapeutics AG's market cap, and Simon Property Group Inc pays a 3.98% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | SPG | |
|---|---|---|
Market Cap | $4.97B | $71.76B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $227.56 |
52-Week Low | $44.34 | $159.93 |
Enterprise Value | $3.32B | $100.24B |
Dividend Yield | — | 3.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SPG trades at $219.49, up 0.33% on the day, with a bearish technical signal despite bullish moving averages. The stock shows strong fundamentals with a 72.7% net income margin in 2025 and consistent earnings beats. Recent news highlights robust Q1 2026 results and a 4% dividend yield, though some analysts express caution on valuation. Cash flow trends indicate increased capital expenditures, with net cash flow turning negative in 2025.
Outlook remains mixed: strong leasing activity and raised FFO guidance support upside, but high debt levels and e-commerce risks weigh on sentiment. Analysts are predominantly neutral with a $214.40 consensus target, slightly below current price. Investors should balance income appeal against valuation concerns and macroeconomic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
